1	Immunosuppressant	Immunosuppressant	_	_	_	_	_	_	_
2	PG490	PG490	_	_	_	_	_	_	_
3	(	(	_	_	_	_	_	_	_
4	triptolide	triptolide	_	_	_	_	_	_	_
5	)	)	_	_	_	_	_	_	_
6	inhibits	inhibit	_	_	_	_	_	_	_
7	T-cell	t-cell	_	_	_	_	_	_	_
8	interleukin-2	interleukin-2	_	_	_	_	_	_	_
9	expression	expression	_	_	_	_	_	_	_
10	at	at	_	_	_	_	_	_	_
11	the	the	_	_	_	_	_	_	_
12	level	level	_	_	_	_	_	_	_
13	of	of	_	_	_	_	_	_	_
14	purine-box/nuclear	purine-box/nuclear	_	_	_	_	_	_	_
15	factor	factor	_	_	_	_	_	_	_
16	of	of	_	_	_	_	_	_	_
17	activated	activate	_	_	_	_	_	_	_
18	T-cells	T-cell	_	_	_	_	_	_	_
19	and	and	_	_	_	_	_	_	_
20	NF-kappaB	NF-kappaB	_	_	_	_	_	_	_
21	transcriptional	transcriptional	_	_	_	_	_	_	_
22	activation	activation	_	_	_	_	_	_	_
23	.	.	_	_	_	_	_	_	_

1	PG490	PG490	_	_	_	_	_	_	_
2	(	(	_	_	_	_	_	_	_
3	triptolide	triptolide	_	_	_	_	_	_	_
4	)	)	_	_	_	_	_	_	_
5	is	be	_	_	_	_	_	_	_
6	a	a	_	_	_	_	_	_	_
7	diterpene	diterpene	_	_	_	_	_	_	_
8	triepoxide	triepoxide	_	_	_	_	_	_	_
9	with	with	_	_	_	_	_	_	_
10	potent	potent	_	_	_	_	_	_	_
11	immunosuppressive	immunosuppressive	_	_	_	_	_	_	_
12	and	and	_	_	_	_	_	_	_
13	antiinflammatory	antiinflammatory	_	_	_	_	_	_	_
14	properties	property	_	_	_	_	_	_	_
15	.	.	_	_	_	_	_	_	_

1	PG490	PG490	_	_	_	_	_	_	_
2	inhibits	inhibit	_	_	_	_	_	_	_
3	interleukin(IL)-2	interleukin(il)-2	_	_	_	_	_	_	_
4	expression	expression	_	_	_	_	_	_	_
5	by	by	_	_	_	_	_	_	_
6	normal	normal	_	_	_	_	_	_	_
7	human	human	_	_	_	_	_	_	_
8	peripheral	peripheral	_	_	_	_	_	_	_
9	blood	blood	_	_	_	_	_	_	_
10	lymphocytes	lymphocyte	_	_	_	_	_	_	_
11	stimulated	stimulate	_	_	_	_	_	_	_
12	with	with	_	_	_	_	_	_	_
13	phorbol	phorbol	_	_	_	_	_	_	_
14	12-myristate	12-myristate	_	_	_	_	_	_	_
15	13-acetate	13-acetate	_	_	_	_	_	_	_
16	(	(	_	_	_	_	_	_	_
17	PMA	PMA	_	_	_	_	_	_	_
18	)	)	_	_	_	_	_	_	_
19	and	and	_	_	_	_	_	_	_
20	antibody	antibody	_	_	_	_	_	_	_
21	to	to	_	_	_	_	_	_	_
22	CD3	CD3	_	_	_	_	_	_	_
23	(	(	_	_	_	_	_	_	_
24	IC50	IC50	_	_	_	_	_	_	_
25	of	of	_	_	_	_	_	_	_
26	10	10	_	_	_	_	_	_	_
27	ng/ml	ng/ml	_	_	_	_	_	_	_
28	)	)	_	_	_	_	_	_	_
29	,	,	_	_	_	_	_	_	_
30	and	and	_	_	_	_	_	_	_
31	with	with	_	_	_	_	_	_	_
32	PMA	PMA	_	_	_	_	_	_	_
33	and	and	_	_	_	_	_	_	_
34	ionomycin	ionomycin	_	_	_	_	_	_	_
35	(	(	_	_	_	_	_	_	_
36	Iono	Iono	_	_	_	_	_	_	_
37	,	,	_	_	_	_	_	_	_
38	IC50	ic50	_	_	_	_	_	_	_
39	of	of	_	_	_	_	_	_	_
40	40	40	_	_	_	_	_	_	_
41	ng/ml	ng/ml	_	_	_	_	_	_	_
42	)	)	_	_	_	_	_	_	_
43	.	.	_	_	_	_	_	_	_

1	In	in	_	_	_	_	_	_	_
2	Jurkat	Jurkat	_	_	_	_	_	_	_
3	T-cells	T-cell	_	_	_	_	_	_	_
4	,	,	_	_	_	_	_	_	_
5	PG490	PG490	_	_	_	_	_	_	_
6	inhibits	inhibit	_	_	_	_	_	_	_
7	PMA/Iono-stimulated	pma/iono-stimulated	_	_	_	_	_	_	_
8	IL-2	il-2	_	_	_	_	_	_	_
9	transcription	transcription	_	_	_	_	_	_	_
10	.	.	_	_	_	_	_	_	_

1	PG490	PG490	_	_	_	_	_	_	_
2	inhibits	inhibit	_	_	_	_	_	_	_
3	the	the	_	_	_	_	_	_	_
4	induction	induction	_	_	_	_	_	_	_
5	of	of	_	_	_	_	_	_	_
6	DNA	DNA	_	_	_	_	_	_	_
7	binding	binding	_	_	_	_	_	_	_
8	activity	activity	_	_	_	_	_	_	_
9	at	at	_	_	_	_	_	_	_
10	the	the	_	_	_	_	_	_	_
11	purine-box/antigen	purine-box/antigen	_	_	_	_	_	_	_
12	receptor	receptor	_	_	_	_	_	_	_
13	response	response	_	_	_	_	_	_	_
14	element	element	_	_	_	_	_	_	_
15	(	(	_	_	_	_	_	_	_
16	ARRE)/nuclear	arre)/nuclear	_	_	_	_	_	_	_
17	factor	factor	_	_	_	_	_	_	_
18	of	of	_	_	_	_	_	_	_
19	activated	activate	_	_	_	_	_	_	_
20	T-cells	t-cell	_	_	_	_	_	_	_
21	(	(	_	_	_	_	_	_	_
22	NF-AT	NF-AT	_	_	_	_	_	_	_
23	)	)	_	_	_	_	_	_	_
24	target	target	_	_	_	_	_	_	_
25	sequence	sequence	_	_	_	_	_	_	_
26	but	but	_	_	_	_	_	_	_
27	not	not	_	_	_	_	_	_	_
28	at	at	_	_	_	_	_	_	_
29	the	the	_	_	_	_	_	_	_
30	NF-kappaB	NF-kappaB	_	_	_	_	_	_	_
31	site	site	_	_	_	_	_	_	_
32	.	.	_	_	_	_	_	_	_

1	PG490	PG490	_	_	_	_	_	_	_
2	can	can	_	_	_	_	_	_	_
3	completely	completely	_	_	_	_	_	_	_
4	inhibit	inhibit	_	_	_	_	_	_	_
5	transcriptional	transcriptional	_	_	_	_	_	_	_
6	activation	activation	_	_	_	_	_	_	_
7	at	at	_	_	_	_	_	_	_
8	the	the	_	_	_	_	_	_	_
9	purine-box/ARRE/NF-AT	purine-box/arre/nf-at	_	_	_	_	_	_	_
10	and	and	_	_	_	_	_	_	_
11	NF-kappaB	NF-kappaB	_	_	_	_	_	_	_
12	target	target	_	_	_	_	_	_	_
13	DNA	dna	_	_	_	_	_	_	_
14	sequences	sequence	_	_	_	_	_	_	_
15	triggered	trigger	_	_	_	_	_	_	_
16	by	by	_	_	_	_	_	_	_
17	all	all	_	_	_	_	_	_	_
18	stimuli	stimulus	_	_	_	_	_	_	_
19	examined	examine	_	_	_	_	_	_	_
20	(	(	_	_	_	_	_	_	_
21	PMA	PMA	_	_	_	_	_	_	_
22	,	,	_	_	_	_	_	_	_
23	PMA/Iono	PMA/Iono	_	_	_	_	_	_	_
24	,	,	_	_	_	_	_	_	_
25	tumor	tumor	_	_	_	_	_	_	_
26	necrosis	necrosis	_	_	_	_	_	_	_
27	factor-alpha	factor-alpha	_	_	_	_	_	_	_
28	)	)	_	_	_	_	_	_	_
29	.	.	_	_	_	_	_	_	_

1	PG490	PG490	_	_	_	_	_	_	_
2	also	also	_	_	_	_	_	_	_
3	inhibits	inhibit	_	_	_	_	_	_	_
4	PMA-stimulated	pma-stimulated	_	_	_	_	_	_	_
5	activation	activation	_	_	_	_	_	_	_
6	of	of	_	_	_	_	_	_	_
7	a	a	_	_	_	_	_	_	_
8	chimeric	chimeric	_	_	_	_	_	_	_
9	transcription	transcription	_	_	_	_	_	_	_
10	factor	factor	_	_	_	_	_	_	_
11	in	in	_	_	_	_	_	_	_
12	which	which	_	_	_	_	_	_	_
13	the	the	_	_	_	_	_	_	_
14	C-terminal	c-terminal	_	_	_	_	_	_	_
15	TA1	TA1	_	_	_	_	_	_	_
16	transactivation	transactivation	_	_	_	_	_	_	_
17	domain	domain	_	_	_	_	_	_	_
18	of	of	_	_	_	_	_	_	_
19	NF-kappaB	NF-kappaB	_	_	_	_	_	_	_
20	p65	p65	_	_	_	_	_	_	_
21	is	be	_	_	_	_	_	_	_
22	fused	fuse	_	_	_	_	_	_	_
23	to	to	_	_	_	_	_	_	_
24	the	the	_	_	_	_	_	_	_
25	DNA	dna	_	_	_	_	_	_	_
26	binding	binding	_	_	_	_	_	_	_
27	domain	domain	_	_	_	_	_	_	_
28	of	of	_	_	_	_	_	_	_
29	GAL4	gal4	_	_	_	_	_	_	_
30	.	.	_	_	_	_	_	_	_

1	In	in	_	_	_	_	_	_	_
2	16HBE	16hbe	_	_	_	_	_	_	_
3	human	human	_	_	_	_	_	_	_
4	bronchial	bronchial	_	_	_	_	_	_	_
5	epithelial	epithelial	_	_	_	_	_	_	_
6	cells	cell	_	_	_	_	_	_	_
7	,	,	_	_	_	_	_	_	_
8	IL-8	il-8	_	_	_	_	_	_	_
9	expression	expression	_	_	_	_	_	_	_
10	is	be	_	_	_	_	_	_	_
11	regulated	regulate	_	_	_	_	_	_	_
12	predominantly	predominantly	_	_	_	_	_	_	_
13	by	by	_	_	_	_	_	_	_
14	NF-kappaB	NF-kappaB	_	_	_	_	_	_	_
15	,	,	_	_	_	_	_	_	_
16	and	and	_	_	_	_	_	_	_
17	PG490	PG490	_	_	_	_	_	_	_
18	but	but	_	_	_	_	_	_	_
19	not	not	_	_	_	_	_	_	_
20	cyclosporin	cyclosporin	_	_	_	_	_	_	_
21	A	a	_	_	_	_	_	_	_
22	can	can	_	_	_	_	_	_	_
23	completely	completely	_	_	_	_	_	_	_
24	inhibit	inhibit	_	_	_	_	_	_	_
25	expression	expression	_	_	_	_	_	_	_
26	of	of	_	_	_	_	_	_	_
27	IL-8	il-8	_	_	_	_	_	_	_
28	.	.	_	_	_	_	_	_	_

1	The	the	_	_	_	_	_	_	_
2	mechanism	mechanism	_	_	_	_	_	_	_
3	of	of	_	_	_	_	_	_	_
4	PG490	pg490	_	_	_	_	_	_	_
5	inhibition	inhibition	_	_	_	_	_	_	_
6	of	of	_	_	_	_	_	_	_
7	cytokine	cytokine	_	_	_	_	_	_	_
8	gene	gene	_	_	_	_	_	_	_
9	expression	expression	_	_	_	_	_	_	_
10	differs	differ	_	_	_	_	_	_	_
11	from	from	_	_	_	_	_	_	_
12	cyclosporin	cyclosporin	_	_	_	_	_	_	_
13	A	a	_	_	_	_	_	_	_
14	and	and	_	_	_	_	_	_	_
15	involves	involve	_	_	_	_	_	_	_
16	nuclear	nuclear	_	_	_	_	_	_	_
17	inhibition	inhibition	_	_	_	_	_	_	_
18	of	of	_	_	_	_	_	_	_
19	transcriptional	transcriptional	_	_	_	_	_	_	_
20	activation	activation	_	_	_	_	_	_	_
21	of	of	_	_	_	_	_	_	_
22	NF-kappaB	NF-kappaB	_	_	_	_	_	_	_
23	and	and	_	_	_	_	_	_	_
24	the	the	_	_	_	_	_	_	_
25	purine-box	purine-box	_	_	_	_	_	_	_
26	regulator	regulator	_	_	_	_	_	_	_
27	operating	operate	_	_	_	_	_	_	_
28	at	at	_	_	_	_	_	_	_
29	the	the	_	_	_	_	_	_	_
30	ARRE/NF-AT	arre/nf-at	_	_	_	_	_	_	_
31	site	site	_	_	_	_	_	_	_
32	at	at	_	_	_	_	_	_	_
33	a	a	_	_	_	_	_	_	_
34	step	step	_	_	_	_	_	_	_
35	after	after	_	_	_	_	_	_	_
36	specific	specific	_	_	_	_	_	_	_
37	DNA	dna	_	_	_	_	_	_	_
38	binding	binding	_	_	_	_	_	_	_
39	.	.	_	_	_	_	_	_	_

